Allogene Therapeutics, Inc. (ALLO) vs Puma Biotechnology, Inc. (PBYI)
A side-by-side comparison of Allogene Therapeutics, Inc. and Puma Biotechnology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALLO
Allogene Therapeutics, Inc.
$1.46HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
PBYI
Puma Biotechnology, Inc.
$9.56HealthcareDelayed quote: Oct 6, 2026, 12:24 PM EDT
Total return — ALLO vs PBYI
growth of $100 · dividends reinvested · last 8yALLO -94.0% (-29.6%/yr)PBYI -77.1% (-16.8%/yr)PBYI compounded faster over this window
ALLO PBYI
ALLO vs PBYI: by the numbers
- •ALLO is the larger company ($502M vs $487M market cap).
- •PBYI is profitable (11.55% net margin) while ALLO runs a net loss (-3566.68%).
- •PBYI grew revenue faster over the past five years (0.29% vs -34.47% CAGR).
Metrics side by side
Valuation
| Metric | ALLO | PBYI |
|---|---|---|
| P/E ratio | N/A | 18.52 |
| Forward P/E | N/A | 25.16 |
| P/S ratio | 108.23 | 2.10 |
| P/B ratio | 1.15 | 3.51 |
| EV / EBITDA | N/A | 10.48 |
| FCF yield | N/A | 8.44% |
Profitability
| Metric | ALLO | PBYI |
|---|---|---|
| Gross margin | 0.00% | 74.83% |
| Operating margin | 0.00% | 13.16% |
| Net margin | -3566.68% | 11.55% |
| ROE | -37.94% | 19.28% |
| ROIC | -34.79% | 18.26% |
Growth (annualized)
| Metric | ALLO | PBYI |
|---|---|---|
| Revenue CAGR (5Y) | -34.47% | 0.29% |
| FCF CAGR (5Y) | N/A | 90.51% |
| Total return CAGR (5Y) | -42.72% | 9.26% |
Frequently asked
- Which has grown faster, ALLO or PBYI?
- Over the past five years, PBYI grew revenue faster — ALLO at a -34.47% CAGR versus PBYI at 0.29%.
- Is ALLO or PBYI more profitable?
- PBYI runs the higher net margin — ALLO at -3566.68% versus PBYI at 11.55%.
- How have ALLO and PBYI total returns compared?
- Over the past 5 years, ALLO delivered -42.72% and PBYI delivered 9.26% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Puma Biotechnology P/E ratioAllogene Therapeutics ROEPuma Biotechnology ROEAllogene Therapeutics operating marginPuma Biotechnology operating marginAllogene Therapeutics revenue growthPuma Biotechnology revenue growthAllogene Therapeutics free cash flowPuma Biotechnology free cash flow
Allogene Therapeutics & Puma Biotechnology appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.